|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 4
2022
Burgers, Luisa D.; Li, Yanfen; Michalakis, Stylianos; Ciurus, Sarah; Zahler, Stefan; Mueller, Rolf und Fuerst, Robert
(2022):
The protein biosynthesis inhibitor vioprolide A evokes anti-angiogenic and pro-survival actions by targeting NOP14 and decreasing VEGF receptor 2and TAZ-signaling.
In: Biomedicine & Pharmacotherapy, Bd. 152, 113174
2021
Burgers, Luisa D.; Luong, Betty; Li, Yanfen; Fabritius, Matthias P.; Michalakis, Stylianos; Reichel, Christoph A.; Mueller, Rolf und Fuerst, Robert
(2021):
The natural product vioprolide A exerts anti-inflammatory actions through inhibition of its cellular target NOP14 and downregulation of importin-dependent NF-kappa B p65 nuclear translocation.
In: Biomedicine & Pharmacotherapy, Bd. 144, 112255
2019
Stark, Anna; Schwenk, Rebecca; Wack, Gesine; Zuchtriegel, Gabriele; Hatemler, Melissa G.; Braeutigam, Jacqueline; Schmidtko, Achim; Reichel, Christoph A.; Bischoff, Iris und Fuerst, Robert
(2019):
Narciclasine exerts anti-inflammatory actions by blocking leukocyte-endothelial cell interactions and down-regulation of the endothelial TNF receptor 1.
In: Faseb Journal, Bd. 33, Nr. 8: S. 8771-8781
2015
Fuchs, Simone; Hsieh, Louise T.; Saarberg, Werner; Erdelmeier, Clemens A. J.; Wichelhaus, Thomas A.; Schaefer, Liliana; Koch, Egon und Fuerst, Robert
(2015):
Haemanthus coccineus extract and its main bioactive component narciclasine display profound anti-inflammatory activities in vitro and in vivo.
In: Journal of Cellular and Molecular Medicine, Bd. 19, Nr. 5: S. 1021-1032
[PDF, 718kB]